



## YmAbs Announces Acceptance of Presentations of Burtomab Data at ASCO 2017 Annual Meeting

May 9, 2017

Pivotal efficacy data for 131I-burtomab treatments of Neuroblastoma CNS Metastases and DIPG has been accepted

**NEW YORK, May 9, 2017** – YmAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that data from its lead compound 131I-burtomab will be presented at the 2017 American Society of Clinical Oncology (ASCO) meeting in Chicago. The titles of the abstracts are available on the ASCO website at [www.asco.org](http://www.asco.org) via ASCO's iPlanner. The full abstracts are scheduled to be published on the ASCO website on May 17 at 5:00PM EDT.

### Leptomeningeal Metastasis from Neuroblastoma

Dr. Kim Kramer from Memorial Sloan Kettering Cancer Center (MSK) presents overall survival data from 80 pediatric patients with CNS and leptomeningeal metastasis from neuroblastoma treated with 131I-burtomab in a poster presentation. Additionally, Dr. Frank Bertholdt from University of Cologne will present comparable historical data from the Central German Childhood Cancer Registry in a poster presentation.

### Diffuse Intrinsic Pontine Glioma (DIPG)

Dr. Mark Souweidane, MSK and Weill Cornell Medicine, will present results of the phase I Study of Convection-Enhanced Delivery (CED) for DIPG treatment in an oral presentation. CED is a technique designed to deliver drugs directly into the brain or tumors. Its ability to bypass the blood-brain barrier, one of the major hurdles in delivering drugs to the brain, has made it a promising drug delivery method for the treatment of primary brain tumor. Dr. Kim Kramer and Dr. Ira Dunkel, MSK, were co-Principal Investigators in the study.

### About YmAbs:

YmAbs is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. In addition, YmAbs utilizes its platform technologies to create next-generation humanized, affinity-matured bispecific antibodies targeting CD2 and B7H3. To further improve our bispecific antibodies, we are collaborating on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. Our treatments could potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs' goal is to drive multiple product candidates in select solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.

To learn more, visit [www.ymabs.com](http://www.ymabs.com).

### SOURCE:

Y-mAbs Therapeutics, Inc.

### CONTACT:

YmAbs Therapeutics, Inc.	Y-mAbs Therapeutics A/S
750 Third Avenue, 9th Floor	Rungtved Strandvej 113
New York, NY 10017	2960 Rungtved Kyst
USA	Denmark
+1 212 847 9844	+45 70 26 14 14
E-mail: <a href="mailto:info@ymabs.com">info@ymabs.com</a>	E-mail: <a href="mailto:info@ymabs.com">info@ymabs.com</a>